 NeoGenomics NASDAQ:NEO was downgraded by Zacks Investment Research from a strong-buy rating to a hold rating in a report issued on Friday, Zacks.com reports. According to Zacks, NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The companys testing services include ... 